Drug Page

New research suggests that clinicians should exercise caution prescribing SNRIs as first-line treatment for mood and anxiety disorders.

A new study tracks the approval of the latest antidepressant, vortioxetine, by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA). The...

In part six of a seven-part “Drugging Our Kids” series by The Mercury News, Karen de Sa and Tracy Seipel unveil California’s top foster...

Contrary to widely-held belief, a new rigorous trial finds that ketamine is ineffective for delirium and pain associated with surgery, and the drug carries harmful side effects.

Medically-induced harm—affecting tens of millions of people worldwide—has taken the field decades to take seriously.

A new study shows that airline pilots are at elevated risk for depression, yet encounter barriers to accessing mental health services.

Researchers found that veterans with both conditions had higher odds of being prescribed second-generation antipsychotics than those presenting with just PTSD.

Important assessment tool found to underestimate the risk for fracture in patients on psychiatric medication.

According to new research, the United States spends over 200 billion annually on treatment and hospitalization for mental health issues, exceeding spending on heart...

Several years after the information was first revealed, a published study has shown how an influential NIMH study doctored the real data about antidepressants and suicidal events in youth.

A new study suggests that depressive symptoms in older adults can be improved with non-invasive behavioral activation techniques. These approaches appear to have a preventative effect, serving to prevent further depressive symptoms from developing.

Researchers suggest that the pharmaceutical industry had a vested interest in using the term “discontinuation” in order to hide the severity of physical dependence and withdrawal reactions many people experience from antidepressants.

A new study finds that elderly individuals using antidepressants are at significantly higher risk for dementia compared to depressed individuals who did not take the drugs.

Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.

Common psychotropic medications may be contributing to the higher rates of physical illnesses and mortality in people diagnosed with mental illnesses.

Two new articles find that rates of ADHD diagnosis and stimulant prescription continue to rise all over the world.

The percentage of seniors in the United States prescribed potentially deadly antipsychotic drugs increases with age. A new study reveals that in the face of serious risks of strokes, fractures, kidney injuries, and death, over seventy-five percent of seniors given antipsychotics do not have a diagnosis for a mental disorder.

-SSRI antidepressant medications contribute to a significant worsening of emotional "rapid cycling" in patients diagnosed with bipolar disorder.

Between 2,150 and 4,100 children suffered from severe malformations connected to valproate prescription.

With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?

A new special issue brings together articles exploring the harmful effects of simultaneous multiple medication use.

An issue of Lancet Psychiatry is devoted to clarifying the lack of efficacy for Zoloft (sertraline).

The Finnish Psychological Association held a meeting in Helsinki on 1 Sept 2014 titled “Mental Health and Medicalization.” I spoke at the meeting and four days later I sent a letter to another speaker, psychiatrist Erkki Isometsä. Professor Isometsä replied: “I will respond to it in detail within a few days..." As "Open Dialogue" is essential in science, I have published my letter to Isometsä here as well as on my own website, although I didn’t succeed in starting a dialogue.

A study released this week in JAMA examined whether giving patients with chronic heart failure and depression the SSRI antidepressant escitalopram (Lexapro) for two...

Two recent court rulings argue that pharmaceutical companies have a first amendment right to market drugs “off-label” with a lack of scientific evidence, threatening...